IN2014DN09717A - - Google Patents
Info
- Publication number
- IN2014DN09717A IN2014DN09717A IN9717DEN2014A IN2014DN09717A IN 2014DN09717 A IN2014DN09717 A IN 2014DN09717A IN 9717DEN2014 A IN9717DEN2014 A IN 9717DEN2014A IN 2014DN09717 A IN2014DN09717 A IN 2014DN09717A
- Authority
- IN
- India
- Prior art keywords
- pdgf
- antibodies
- inhibiting
- binding
- pdgfra
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261637372P | 2012-04-24 | 2012-04-24 | |
EP12165314 | 2012-04-24 | ||
US201261727231P | 2012-11-16 | 2012-11-16 | |
EP12192943 | 2012-11-16 | ||
PCT/EP2013/058513 WO2013160359A1 (fr) | 2012-04-24 | 2013-04-24 | Anticorps anti-pdgf-c |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN09717A true IN2014DN09717A (fr) | 2015-07-31 |
Family
ID=49482233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN9717DEN2014 IN2014DN09717A (fr) | 2012-04-24 | 2014-11-18 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9884910B2 (fr) |
EP (1) | EP2841454A1 (fr) |
JP (1) | JP2015515487A (fr) |
KR (1) | KR20150005631A (fr) |
CN (1) | CN104321343A (fr) |
AU (1) | AU2013254690B2 (fr) |
BR (1) | BR112014025560A2 (fr) |
CA (1) | CA2871528A1 (fr) |
IN (1) | IN2014DN09717A (fr) |
MX (1) | MX2014012843A (fr) |
NZ (2) | NZ700274A (fr) |
RU (1) | RU2014140116A (fr) |
WO (1) | WO2013160359A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013160359A1 (fr) | 2012-04-24 | 2013-10-31 | Thrombogenics N.V. | Anticorps anti-pdgf-c |
CN108348605B (zh) * | 2015-11-10 | 2023-06-09 | 帕拉卡林治疗公司 | 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌 |
MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
JP7437000B2 (ja) * | 2016-07-01 | 2024-02-22 | パラクライン セラピューティクス アーベー | Pdgf-ccの阻害のための方法および組成物 |
KR101943083B1 (ko) * | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
KR101943081B1 (ko) * | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
US20200390729A1 (en) * | 2017-12-04 | 2020-12-17 | Laboratorios Salvat, S.A. | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
WO1991019515A1 (fr) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Mutant du domaine constant d'immunoglobulines oligomeres presentant une activite cytolytique accrue a mediation de complement |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0564531B1 (fr) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees |
US5304118A (en) | 1992-12-16 | 1994-04-19 | Trese Michael T | Method for performing a vitrectomy on an eye |
WO1999002567A2 (fr) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions et procedes destines a des homoconjugues d'anticorps qui induisent l'arret de la croissance ou l'apoptose de cellules tumorales |
ES2389387T3 (es) | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Polipéptidos homólogos de VEGF y de BMP1 |
CN1330664A (zh) | 1998-09-30 | 2002-01-09 | 路德维格癌症研究所 | 血小板衍生生长因子c、其编码dna及其应用 |
US6432673B1 (en) * | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
JP4739526B2 (ja) * | 1998-12-07 | 2011-08-03 | ザイモジェネティクス, インコーポレイテッド | 成長因子相同体zvegf3 |
WO2001028586A1 (fr) | 1999-10-21 | 2001-04-26 | Zymogenetics, Inc. | Traitement de la fibrose |
EP1267627A1 (fr) * | 2000-03-28 | 2003-01-02 | Ludwig Institute For Cancer Research | Animaux transgeniques non humains exprimant un facteur de croissance c derive de plaquettes (pdgf-c) et utilisations |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
WO2005011742A1 (fr) * | 2003-07-25 | 2005-02-10 | Zymogenetics, Inc. | Procede de traitement de carcinome hepatocellulaire |
WO2005087812A1 (fr) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Substances d'anticorps polyvalentes et procedes pour la famille vegf/pdgf des facteurs de croissance |
WO2007124308A2 (fr) | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research | Méthodes et compositions pour moduler la barrière hémato-neurale |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
WO2010033913A1 (fr) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Anticorps, analogues et leurs utilisations |
WO2013160359A1 (fr) | 2012-04-24 | 2013-10-31 | Thrombogenics N.V. | Anticorps anti-pdgf-c |
-
2013
- 2013-04-24 WO PCT/EP2013/058513 patent/WO2013160359A1/fr active Application Filing
- 2013-04-24 NZ NZ700274A patent/NZ700274A/en not_active IP Right Cessation
- 2013-04-24 MX MX2014012843A patent/MX2014012843A/es unknown
- 2013-04-24 CN CN201380021028.7A patent/CN104321343A/zh active Pending
- 2013-04-24 BR BR112014025560A patent/BR112014025560A2/pt not_active IP Right Cessation
- 2013-04-24 AU AU2013254690A patent/AU2013254690B2/en not_active Expired - Fee Related
- 2013-04-24 CA CA2871528A patent/CA2871528A1/fr not_active Abandoned
- 2013-04-24 US US14/404,052 patent/US9884910B2/en not_active Expired - Fee Related
- 2013-04-24 NZ NZ724395A patent/NZ724395A/en unknown
- 2013-04-24 EP EP13722708.8A patent/EP2841454A1/fr not_active Withdrawn
- 2013-04-24 RU RU2014140116A patent/RU2014140116A/ru not_active Application Discontinuation
- 2013-04-24 JP JP2015507520A patent/JP2015515487A/ja active Pending
- 2013-04-24 KR KR1020147032459A patent/KR20150005631A/ko not_active Application Discontinuation
-
2014
- 2014-11-18 IN IN9717DEN2014 patent/IN2014DN09717A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150005631A (ko) | 2015-01-14 |
AU2013254690A1 (en) | 2014-11-06 |
BR112014025560A2 (pt) | 2017-07-04 |
CN104321343A (zh) | 2015-01-28 |
JP2015515487A (ja) | 2015-05-28 |
CA2871528A1 (fr) | 2013-10-31 |
US9884910B2 (en) | 2018-02-06 |
AU2013254690B2 (en) | 2017-12-07 |
RU2014140116A (ru) | 2016-06-10 |
MX2014012843A (es) | 2017-01-23 |
WO2013160359A1 (fr) | 2013-10-31 |
NZ700274A (en) | 2016-10-28 |
EP2841454A1 (fr) | 2015-03-04 |
NZ724395A (en) | 2018-03-23 |
US20150232546A1 (en) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
MX2014015830A (es) | Anticuerpos lsr y usos de los mismos para el tratamiento de cancer. | |
SG2014008304A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
IN2014DN09717A (fr) | ||
MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
WO2014163714A3 (fr) | Conjugués médicament-anticorps | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
MX362497B (es) | Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo. | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
IL232339A0 (en) | 32rf10c antibodies, and their uses for cancer treatment | |
IL232340A0 (en) | lsr antibodies, and their uses for cancer treatment |